Candel Therapeutics, Inc. (CADL) Reports Sustained Immune Remodeling in Phase 3 Prostate Study

Candel Therapeutics reported AI-enabled digital pathology from its completed Phase 3 aglatimagene study showing significantly increased intratumoral lymphocyte infiltration vs placebo more than two years post-EBRT, supporting prior disease-free survival and pathologic outcome findings.Material Deta…